教育经历：

(1) 2005-08至2008-07, 南方医科大学, 肝胆外科, 博士

(2) 1997-08至2000-07, 第一军医大学, 肝胆外科, 硕士

(3) 1992-08至1997-07, 第一军医大学, 临床医学, 学士

科研与学术工作经历：

(1) 2010-12至现在, 南方医科大学, 南方医院, 副教授

(2) 2004-01至2010-11, 南方医科大学, 南方医院, 讲师

(3) 2002-09至2003-12, 第一军医大学, 珠江医院, 讲师

(4) 2000-08至2002-08, 第一军医大学, 珠江医院, 助教

(5) 2014-01至2015-12, Mayo Clinic, 博士后

1.胆管癌（肝内胆管细胞癌），肝癌的病因发生及治疗；2.肝移植

1.Wang Y# , Ding X# , Wang S # , Moser CD# , Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr FE, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR*. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett，2016, 380(1): 163-173.（IF=7.36）

2. Wang Y, Shaleh HM, Ding X, Wang S, Chaiteerakij R, Zakharia K, Allotey LK, Mohamed EA, Moser CD, Alberts S, Gozgit JM, Borad MJ, Roberts LR*. Differential Antitumor Effects of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient-Derived Xenograft Mouse Model Expressing an FGFR2-CCDC6 Fusion Protein. Hepatology, 2015, 621(SI): 1165A-1166A. （IF=14.679）

3. Wu T # , Jiang X# , Zhang X, Wu B, Xu B, Liu X, Zheng L*, Wang Y*. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control , 2021, 28: 1149424578. doi: 10.1177/1073274821989314. （IF=3.103）

4. Zakharia K# , Miyabe K# , Wang Y# , Wu D# , Moser CD, Borad MJ, Roberts LR*. Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Transl Oncol, 2019, 12(1): 143-153. （IF=3.558）

5. Xiao W, Zhao W, Li L, Wu Q, Zhu L, Zhang Q, Dai W, Wang Y*, Zhang B*. Preliminary investigation of the role of BTB domain-containing 3 gene in the proliferation and metastasis of hepatocellular carcinoma. Oncol Lett, 2017, 14(2): 2505-2510. （IF=2.311）